Bicara Therapeutics Inc.
BCAX
$22.38
-$0.54-2.36%
NASDAQ
| 12/31/2025 | 09/30/2025 | ||||
|---|---|---|---|---|---|
| Revenue | -- | -- | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -- | -- | |||
| Cost of Revenue | -- | -- | |||
| Gross Profit | -- | -- | |||
| SG&A Expenses | 5.60% | 6.66% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | 1.10% | 27.04% | |||
| Operating Income | -1.10% | -27.04% | |||
| Income Before Tax | -2.87% | -32.76% | |||
| Income Tax Expenses | 32.50% | -23.08% | |||
| Earnings from Continuing Operations | -2.91% | -32.65% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | -2.91% | -32.65% | |||
| EBIT | -1.10% | -27.04% | |||
| EBITDA | -1.05% | -27.04% | |||
| EPS Basic | -1.83% | -32.58% | |||
| Normalized Basic EPS | -1.78% | -32.68% | |||
| EPS Diluted | -1.83% | -32.58% | |||
| Normalized Diluted EPS | -1.78% | -32.68% | |||
| Average Basic Shares Outstanding | 1.06% | 0.05% | |||
| Average Diluted Shares Outstanding | 1.06% | 0.05% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||